Clinical Cancer Research, Vol 3, Issue 8 1443-1451, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family

FA Montero-Julian, H Brailly, C Sautes, I Joyeux, T Dorval, V Mosseri, K Yasukawa, J Wijdenes, A Adler, I Gorin, WH Fridman and E Tartour
Immunotech S.A., 130 Avenue de Lattre de Tassigny, BP 177 F, 13276 Marseille Cedex 09, France.

gp130 acts as a common transducing signal chain for all receptors belonging to the interleukin (IL)-6 receptor family. The IL-6-related cytokines [IL-6, IL-11, oncostatin M (OSM), leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin] often modulate tumor phenotype and control the proliferation of many tumor cell lines. We demonstrate that melanoma cell lines release, in vitro and in vivo (when transplanted in nude mice), soluble gp130 (sgp130), a potential antagonist of cytokines from the IL-6 family. Biochemical analysis revealed that sgp130 derived from melanoma patients' sera or from culture supernatants of melanoma cell lines is a Mr 104,000 protein that resolved after deglycosylation as a Mr 58,000 protein. PCR and Northern blot analysis only identified one gp130 membrane mRNA, suggesting that the soluble form of gp130 is generated by proteolytic cleavage. OSM reproducibly increases sgp130 released by melanoma cell lines, whereas leukemia inhibitory factor stimulates the production of sgp130 in only one of three cell lines tested. This tumor-derived sgp130 is functional because it binds in solution to the IL-6-soluble IL-6 receptor (gp80) complex. Recombinant sgp130 inhibits the growth inhibitory activity of the IL-6-soluble IL-6 receptor complex and OSM on some melanoma cell lines. Therefore, this soluble gp130 represents a natural antagonist of cytokines from the IL-6 family.

This article has been cited by other articles:

				J. S. Fitzgerald, T. G. Poehlmann, E. Schleussner, and U. R. Markert Trophoblast invasion: the role of intracellular cytokine signalling via signal transducer and activator of transcription 3 (STAT3) Hum. Reprod. Update, April 17, 2008; (2008) dmn010v1. [Abstract] [Full Text] [PDF]

				H. Song and H. Lim Evidence for heterodimeric association of leukemia inhibitory factor (LIF) receptor and gp130 in the mouse uterus for LIF signaling during blastocyst implantation Reproduction, February 1, 2006; 131(2): 341 - 349. [Abstract] [Full Text] [PDF]

				J. R. A. Sherwin, S. K. Smith, A. Wilson, and A. M. Sharkey Soluble gp130 is Up-Regulated in the Implantation Window and Shows Altered Secretion in Patients with Primary Unexplained Infertility J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3953 - 3960. [Abstract] [Full Text] [PDF]

				S. A. JONES, S. HORIUCHI, N. TOPLEY, N. YAMAMOTO, and G. M. FULLER The soluble interleukin 6 receptor: mechanisms of production and implications in disease FASEB J, January 1, 2001; 15(1): 43 - 58. [Abstract] [Full Text] [PDF]

				C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text]

				J. Sammons, N. Ahmed, M.A. Khokher, and H.T. Hassan Mechanisms Mediating the Inhibitory Effect of All-Trans Retinoic Acid on Primitive Hematopoietic Stem Cells in Human Long-Term Bone Marrow Culture Stem Cells, May 1, 2000; 18(3): 214 - 219. [Abstract] [Full Text]

				E. Tartour, F. Fossiez, I. Joyeux, A. Galinha, A. Gey, E. Claret, X. Sastre-Garau, J. Couturier, V. Mosseri, V. Vives, et al. Interleukin 17, a T-cell-derived Cytokine, Promotes Tumorigenicity of Human Cervical Tumors in Nude Mice Cancer Res., August 1, 1999; 59(15): 3698 - 3704. [Abstract] [Full Text] [PDF]

				G. C. A. Elson, P. Graber, C. Losberger, S. Herren, D. Gretener, L. N. Menoud, T. N. C. Wells, M. H. Kosco-Vilbois, and J.-F. Gauchat Cytokine-Like Factor-1, a Novel Soluble Protein, Shares Homology with Members of the Cytokine Type I Receptor Family J. Immunol., August 1, 1998; 161(3): 1371 - 1379. [Abstract] [Full Text] [PDF]